logo-loader

Medicus Pharma unveils pricing of financing to advance skin cancer treatment

Published: 08:37 07 Mar 2025 EST

Medicus Pharma - Medicus Pharma unveils pricing of financing to advance skin cancer treatment

Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its Tier II Regulation A offering, aiming to raise approximately $4.2 million through the sale of 1.49 million units at $2.80 per unit.

Each unit includes one common share and one warrant, with the warrants exercisable at $2.80 per share for a five-year period.

The proceeds from the offering will primarily support Medicus Pharma's Phase 2 proof-of-concept clinical trial for a doxorubicin tip-loaded dissolvable microarray needle skin patch designed to treat basal cell carcinoma.

The company may also use the funds to expand the trial into a pivotal study or explore applications for other non-melanoma skin diseases.

Any remaining proceeds will support general corporate activities and working capital.

The company expects the offering to close on March 10.

Medicus Pharma shares rationale as CD228V becomes lead development priority

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug...

1 week, 2 days ago